Novo Nordisk (NOVOB DC) wegovy pill 25mg showed greater mean weight loss vs. Orforglipron (LLY) 36mg in population-adjusted indirect treatment comparison
Importance
Level 1
- Population-adjusted indirect treatment comparison uses data from oasis 4 & attain-1 clinical trials.
- In separate patient preference study, 84% favoured wegovy pill 25mg-like treatment profile vs. Orforglipron-like profile.
- Orforglipron 36mg treatment had about 14 times higher discontinuation odds due to gastrointestinal adverse events vs wegovy pill 25mg.
#ELI LILLY & CO#LLY.US#NOVO NORDISK A/S#NOVOB.DC#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#EUROPEAN EQUITIES